UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCBNov 7 2011

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia^® (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9. The data sets include new findings on patient-reported improvements in quality of life measures, including work and household productivity, in patients taking Cimzia^®, as well as other clinical response measures.

"The inability to participate in everyday activities, like daily chores or preparing dinner, is a source of frustration for many rheumatoid arthritis patients," said Kathleen Bos, MD, Vice President, U.S. Medical Affairs, UCB, Inc. "The new data presented at ACR demonstrate that patients treated with Cimzia^® experienced improvements in work and household productivity—two significant measures of a patient's overall quality of life."

Cimzia is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

Following is a guide to Cimzia posters and other UCB-sponsored research being exhibited during ACR. Posters will be presented at various times from Sunday, November 6-Tuesday, November 8, 2011.

• Efficacy, Safety, and Improvements in Work Productivity and Daily Activities with Certolizumab Pegol (CZP) After Incomplete Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Patients with Low to Moderate Disease Activity
  • In RA patients with longstanding low to moderate disease activity, the addition of CZP to non-biologic DMARDs was well tolerated and associated with increased rates of remission, prevention of disease worsening, and improved work productivity and daily activity.
  • 2214 - Tuesday, November 8, 9:00 am - 6:00 pm, Poster Hall
• Baseline Tender Joint Count Scores Predict Long-Term Household Productivity in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol Plus Methotrexate
  • At baseline (BL) higher tender/swollen joint counts (TJC/SJC) scores were associated with increased impairment in household productivity. Improvements in household productivity were seen with CZP treatment in both patients with lower versus higher BL TJC scores, with greater improvements in patients with lowest BL TJC scores.
  • 1245 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall
• Expectations of Treatment Goals and Goal-Setting Practices in People with Rheumatoid Arthritis
  • A new survey of people living with RA shows that a targeted approach to successful disease management means setting personal, social, and treatment goals and monitoring progress to achieve these goals. The survey also found that respondents wanted guidance from their HCPs in determining and setting these goals to assess for themselves whether their treatment is working. As more treatment options become available for RA, it's likely that the expectations of people with RA will increase as well.
  • 106 - Sunday, November 6, 9:00 am - 6:00 pm, Poster Hall

RAPID3 Data

• RAPID3 (Routine Assessment of Patient Index Data 3) At Week 12 Predicts Progression of Joint Damage At Year 1 in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol Plus Methotrexate
  • 445 - Sunday, November 6, 9:00 am - 6:00 pm, Poster Hall
• Association of ACR Clinical Responses with CDAI (Clinical Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data 3) Indices of Disease Activity in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol Plus Methotrexate
  • 1252 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall
• Patient-Reported Disease Activity Including Joint Assessment: A Comparison of RADAI (Rheumatoid Arthritis Disease Activity Index) and RAPID3 (Routine Assessment of Patient Index Data 3) in Patients Treated with Certolizumab Pegol Over 12 Weeks
  • 1230 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall

Other UCB-Sponsored Research

• Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study
  • 1253 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall
• Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients with Rheumatoid Arthritis Receiving Certolizumab Pegol
  • 1248 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall
• Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Japanese Rheumatoid Arthritis Patients with An Inadequate Response to Methotrexate
  • 1218 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall
• Efficacy and Safety of Certolizumab Pegol without Methotrexate Co-Administration in Japanese Patients with Active Rheumatoid Arthritis
• 1220 - Monday, November 7, 9:00 am - 6:00 pm, Poster Hall